Related Experiment Video
Updated: Jul 4, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
[Advances in the targeted treatment of non-small cell lung cancer]
Lea Ruge1, Felix John1, Heather Scharpenseel1
1Klinik I für Innere Medizin, Universitätsklinikum Köln, Kerpener Str. 62, 50937, Köln, Deutschland.
Abstract:
Non-small cell lung cancer (NSCLC) paradigmatically shows the potential of personalized and therefore precise cancer treatment. For around one third of the patients, predominantly suffering from adenocarcinoma, targetable driver mutations could be characterized in the meantime. Targeted therapies, mostly with kinase inhibitors, achieve impressive advances in the prolongation of overall survival often over many years and excellent quality of life in patients with advanced NSCLC. Targeted treatment is also increasingly evaluated as adjuvant or neoadjuvant treatment in early inoperable stages of NSCLC. An absolute prerequisite for the use of personalized treatment is upfront broad molecular diagnostics before the decision on first line treatment. The limitations of personalized treatment are the so far unavoidable development of resistance mutations and increasing clonal heterogeneity during the course of the treatment. Approaches to further improve treatment results comprise the development of next-generation inhibitors, the combination of targeted substances, also with chemotherapy and the use of new immunoconjugates.
Insights
Precise cancer treatment for non-small cell lung cancer (NSCLC) uses targeted therapies based on driver mutations. While effective, resistance and heterogeneity pose challenges, driving research into next-generation inhibitors and combination treatments.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Context:
- Non-small cell lung cancer (NSCLC) treatment landscape.
- Advancements in identifying targetable driver mutations, particularly in adenocarcinoma.
- Emergence of targeted therapies, primarily kinase inhibitors, for advanced NSCLC.
Purpose:
- To highlight the efficacy of targeted therapies in prolonging survival and improving quality of life for advanced NSCLC patients.
- To discuss the role of targeted treatment in early-stage, inoperable NSCLC.
- To emphasize the necessity of comprehensive molecular diagnostics for personalized NSCLC treatment.
Summary:
- Targeted therapies, guided by molecular diagnostics, offer significant survival benefits for NSCLC patients with specific driver mutations.
- Limitations include the development of resistance mutations and clonal heterogeneity during treatment.
- Future strategies involve next-generation inhibitors, combination therapies (including chemotherapy), and novel immunoconjugates.
Impact:
- Personalized medicine in NSCLC demonstrates significant progress in patient outcomes.
- Ongoing research aims to overcome treatment resistance and improve long-term efficacy.
- Development of novel therapeutic strategies promises further advancements in NSCLC management.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Tumor Immunotherapy